The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2020 | Ibrutinib: use in small CLL subgroups only?
Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, disputes the use of ibrutinib in small subgroups vs all patients with chronic lymphocytic leukemia (CLL). Prof. Cymbalista contends that due to the potential toxicities, the indication of chemo-immunotherapy should be narrowed to patients with mutated IGHV. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
